Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clostridia cluster XIVa strain relative Dorea longicatena, live
- Development stage
- Unknown
- Lead developer
- Vedanta Biosciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Clostridia cluster XIVa strain relative Dorea longicatena, live, is a specific bacterial strain used as a component of **VE303**, an investigational live biotherapeutic product (LBP) developed by **Vedanta Biosciences**. This strain belongs to the Clostridia cluster XIVa, a group of commensal bacteria known for their role in maintaining gut homeostasis. In the context of treating **Clostridioides difficile infection (CDI)**, this strain works as part of a defined consortium of eight clonal bacterial strains. Its mechanism of action involves restoring the gut microbiota to provide colonization resistance against *C. difficile*. This is achieved through competitive exclusion, nutrient competition, and the modulation of the metabolic environment—specifically by influencing bile acid metabolism to inhibit *C. difficile* spore germination and vegetative growth. VE303 is currently being evaluated in Phase 3 clinical trials for the prevention of recurrent CDI.
- Other names
- Dorea longicatenaClostridia cluster XIVa strain
Beyond the preview
Go deeper on Clostridia cluster XIVa strain relative Dorea longicatena, live.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clostridia cluster XIVa strain relative Dorea longicatena, live.